Optimizing Treatment Decisions in Platinum-Resistant Ovarian Cancer: Evidence, Sequencing, and Understanding Patient-Centered Care Through Case-Based Learning

Activity Overview

Platinum-resistant ovarian cancer (PROC) remains an area of significant unmet need, where treatment goals focus on prolonging survival while preserving quality of life. As new therapies emerge and the treatment landscape rapidly evolves, clinicians must navigate increasingly complex decisions regarding biomarker testing, treatment sequencing, efficacy expectations, toxicity management, and patient preferences.  This highly interactive, case-based educational program will begin with a competitive landscape update reviewing available and emerging therapies in PROC, including efficacy benchmarks, safety considerations, and evolving clinical evidence. Faculty will then guide participants through real-world patient scenarios that explore biomarker-driven and biomarker-agnostic decision-making, sequencing strategies, management of treatment-related adverse events, and practical treatment selection considerations. Throughout the discussion, faculty will examine how recent and emerging data may influence future standards of care and improve the patient experience.   The program will emphasize translating evidence into practice, helping clinicians present the best treatment options for their patients.  

The GOG Foundation, Inc. is grateful for our commercial supporter for their unrestricted educational grant associated with this Symposium: Corcept Therapeutics

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

After participating in this activity, learners will be able to: 

1. Assess the current and emerging treatment landscape for platinum-resistant ovarian cancer, including key efficacy, safety, and patient-centered considerations. 
2. Evaluate the role of biomarkers and molecular testing in treatment selection and understand emerging evidence regarding their predictive utility. 
3. Apply available clinical trial data to treatment sequencing decisions through evidence-based case discussions. 
4. Develop strategies for managing treatment-related adverse events while maintaining quality of life in patients with PROC. 
5. Incorporate evolving evidence into individualized treatment plans through scenario-based clinical decision making.